COVID-19 (Coronavirus): Pharmacologic nuclear stress testing

July 15, 2021

This article was revised on July 15, 2021, to update the coverage position.

Effective July 15, 2021, AmeriHealth ​has resumed medical necessity reviews for new prior authorization requests for a pharmacologic stress test with nuclear imaging in lieu of exercise stress testing.

AIM guidelines

For AmeriHealth plans that are subject to radiology utilization management through AIM Specialty Health® (AIM) for outpatient non-emergent diagnostic imaging services and certain high-technology radiology services, AIM will apply the above coverage criteria to determine the medical necessity for these services.

AmeriHealth is committed to providing our members with access to the care they need during the COVID-19 pandemic. We encourage all AmeriHealth members and providers to visit our dedicated AmeriHealth New Jersey and AmeriHealth Pennsylvania COVID-19 webpages regularly for the latest news and updates. We will continue to evaluate member needs as the situation changes.

To view AIM’s current and future guidelines, go to the Resources section of AIM’s website.

Learn more

For information on the impacted policy and a list of eligible procedure codes, read the Medical and Claim Payment Policy News Article.​